Overview
Danny is an analytics platform which is able to evaluate massive amounts of real-world data from multiple sources in the oncology and cardiology fields.
Danny provides comprehensive searches, in-depth analyses, predictions and treatment solutions to physicians, researchers and payers.
The platform is powered by SAP HANA – the world’s leading database platform.
Danny Platform’s homepage offers fast access to these main applications – Danny Analytics and Danny Predictions.
Highlights
Security
- EU General Data Protection Regulation (GDPR) compliance
- Data is de-identified to protect the privacy of patient
- HIPPA compliance
- Well-structured authorization policy
System Integration
- Can be installed on-premises or on a private cloud between oncology centers
- It can extract data from any EHR or HIS systems
- It can be integrated into any payers’ database
UI & Velocity
- Quick and easy access to real-world data analytics
- Intuitive user interface
- Application flexibility – specific access level based on your preferred package
Add-on Applications
Danny’s Launchpad Home Page offers fast access to these main applications
Use cases
Physicians / Real World Evidence
The application provides physicians with immediate summary of healthcare data – in aggregate or of individual patients – for delivery of high-quality cost-effective care. Danny Analytics provides statistical data, benchmarks and real-world evidence of therapeutics. Predictive analytics evaluates based on retrospective data for extrapolation of clinically important endpoints
Pharmaceutical Industry
Danny enables better tracking and evaluation of real-world data to uncover newly approved drug adaptation patterns, market access, and drug effectiveness. Cost-benefit analyses and economic evaluations using accepted models with real-world evidence for survival extrapolations and ICER calculations, in support of HTA submissions
Payers
Due to rising costs of therapeutics, there is an urgent need to move away from fee-for-service toward performance-based care. As such, evaluating effectiveness of drugs and comparators based on clinical and real-world evidence are critically important. Danny provides pharmacoeconomic models to evaluate and extrapolate survival and costs based on clinical and local data for cost-effectiveness analyses. This gives budgetary predictability and assessment of effectiveness within public budget spending
CROs/Patient Recruitments
Danny Analytics provides real-time access to patients eligibility for clinical trials of interest. Using pre-defined inclusion and exclusion criteria, eligible patients are automatically updated for improved efficiency and reduced costs in patient recruitment
The algorithm achieved by Sqilline is the first of its kind in the CEE region.
It has the full potential to provide the necessary tools for real-time assessment of the benefits and effects of newly approved drugs. This will ensure the use of effective therapies for patients, which is of key importance for the future development of healthcare in our country
DR. BORISLAV BORISSOV
Former director of Bulgarian Drug Agency and member of International Society for Pharmacoeconomics and Outcomes Research.
For us, oncologists, this way of collecting and analyzing Big Data in the broadest possible way is invaluable.
It enables us to make conclusions based on large amount of important information when deciding on the appropriate therapy for patients. Danny Analytics give us access to specific parameters such as five-year overall survival, progression-free survival, etc. All this is of the utmost importance for the fate of our patients - especially when we need to make the best decision quickly.
PROF. DR. GALINA KURTEVA
Head of Medical Oncology Clinic, University Oncology Hospital, Sofia, Bulgaria
We will be provided with enormous volume of data which is quick and easy to access.
It encompasses large time periods and reports on the patient's condition and the results of therapies for long-term observation and continuous follow-ups. This type of application would also expedite the use of medical devices in healthcare technology assessments (HTAs) for areas where they still have not be used.
PROF. DR. IVO PETROV
Medical Director and Head of Cardiology and Angiology at Acibadem City Clinic Sofia, national cardiology consultant
Experience Danny and its benefits for your organization.
Request a Demo